A citation-based method for searching scientific literature

Shun Lu, Jian Fang, Xingya Li, Lejie Cao, Jianying Zhou, Qisen Guo, Zongan Liang, Ying Cheng, Liyan Jiang, Nong Yang, Zhigang Han, Jianhua Shi, Yuan Chen, Hua Xu, Helong Zhang, Gongyan Chen, Rui Ma, Sanyuan Sun, Yun Fan, Jing Li, Xian Luo, Linfang Wang, Yongxin Ren, Weiguo Su. Lancet Respir Med 2021
Times Cited: 46







List of co-cited articles
542 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
281
71

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
308
69

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
168
56

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
398
43

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski,[...]. Lancet Oncol 2020
196
41

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Garrett M Frampton, Siraj M Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M Bauer, Mikhail Akimov, Jose A Bufill, Carrie Lee, David Jentz,[...]. Cancer Discov 2015
481
39

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Joanna H Tong, Sai F Yeung, Anthony W H Chan, Lau Y Chung, Shuk L Chau, Raymond Wai Ming Lung, Carol Y Tong, Chit Chow, Edith K Y Tin, Yau H Yu,[...]. Clin Cancer Res 2016
259
39

MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
90
34

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Alexa B Schrock, Garrett M Frampton, James Suh, Zachary R Chalmers, Mark Rosenzweig, Rachel L Erlich, Balazs Halmos, Jonathan Goldman, Patrick Forde, Kurt Leuenberger,[...]. J Thorac Oncol 2016
217
32

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip,[...]. J Clin Oncol 2018
176
32


PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, C A Shu, R Umeton, J Montecalvo, A Ni, R Chen, J Dienstag, C Mrad, I Bergagnini,[...]. Ann Oncol 2018
159
28

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen,[...]. Science 2007
28

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen,[...]. Clin Cancer Res 2020
84
26

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
Toshio Fujino, Yoshihisa Kobayashi, Kenichi Suda, Takamasa Koga, Masaya Nishino, Shuta Ohara, Masato Chiba, Masaki Shimoji, Kenji Tomizawa, Toshiki Takemoto,[...]. J Thorac Oncol 2019
68
23

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Xuewen Liu, Yuxia Jia, Mark B Stoopler, Yufeng Shen, Haiying Cheng, Jinli Chen, Mahesh Mansukhani, Sanjay Koul, Balazs Halmos, Alain C Borczuk. J Clin Oncol 2016
227
23

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin,[...]. Cancer Discov 2015
414
21

DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.
Kurtis D Davies, Aprille Lomboy, Carolyn A Lawrence, Michael Yourshaw, Gregary T Bocsi, D Ross Camidge, Dara L Aisner. J Thorac Oncol 2019
69
21

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
507
21

Targeting MET Dysregulation in Cancer.
Gonzalo Recondo, Jianwei Che, Pasi A Jänne, Mark M Awad. Cancer Discov 2020
44
22

Crizotinib in Patients With MET-Amplified NSCLC.
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, Sai-Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I Shapiro, Mark A Socinski, Danielle A Murphy, Umberto Conte,[...]. J Thorac Oncol 2021
35
28

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.
Lorenza Landi, Rita Chiari, Marcello Tiseo, Federica D'Incà, Claudio Dazzi, Antonio Chella, Angelo Delmonte, Laura Bonanno, Diana Giannarelli, Diego Luigi Cortinovis,[...]. Clin Cancer Res 2019
96
21

Savolitinib: First Approval.
Anthony Markham. Drugs 2021
19
52

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
Huy Gia Vuong, An Thi Nhat Ho, Ahmed M A Altibi, Tadao Nakazawa, Ryohei Katoh, Tetsuo Kondo. Lung Cancer 2018
61
19


Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, D Ross Camidge. J Thorac Oncol 2017
215
17

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
Robin Guo, Lynne D Berry, Dara L Aisner, Jamie Sheren, Theresa Boyle, Paul A Bunn, Bruce E Johnson, David J Kwiatkowski, Alexander Drilon, Lynette M Sholl,[...]. J Thorac Oncol 2019
65
17

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
G R Oxnard, J C-H Yang, H Yu, S-W Kim, H Saka, L Horn, K Goto, Y Ohe, H Mann, K S Thress,[...]. Ann Oncol 2020
195
17

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
17

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
Geoffrey R Oxnard, Yuebi Hu, Kathryn F Mileham, Hatim Husain, Daniel B Costa, Philip Tracy, Nora Feeney, Lynette M Sholl, Suzanne E Dahlberg, Amanda J Redig,[...]. JAMA Oncol 2018
390
17

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
James Bean, Cameron Brennan, Jin-Yuan Shih, Gregory Riely, Agnes Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, Janos Szoke, Stephen Broderick,[...]. Proc Natl Acad Sci U S A 2007
17

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
M Schuler, R Berardi, W-T Lim, M de Jonge, T M Bauer, A Azaro, M Gottfried, J-Y Han, D H Lee, M Wollner,[...]. Ann Oncol 2020
44
18

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.
Qiming Wang, Sen Yang, Kai Wang, Shi-Yong Sun. J Hematol Oncol 2019
113
17

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Lars D Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A Tovar, Curt J Essenburg, Zachary Madaj, Harrah Chiang, David Briere, Jill Hallin, Pedro P Lopez-Casas,[...]. Clin Cancer Res 2017
81
15

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
Toni K Choueiri, Daniel Y C Heng, Jae Lyun Lee, Mathilde Cancel, Remy B Verheijen, Anders Mellemgaard, Lone H Ottesen, Melanie M Frigault, Anne L'Hernault, Zsolt Szijgyarto,[...]. JAMA Oncol 2020
65
15

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
15

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
Ravi Salgia, Martin Sattler, Juergen Scheele, Christopher Stroh, Enriqueta Felip. Cancer Treat Rev 2020
40
17

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
15

Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Sinéad A Noonan, Lynne Berry, Xian Lu, Dexiang Gao, Anna E Barón, Patrick Chesnut, Jamie Sheren, Dara L Aisner, Dan Merrick, Robert C Doebele,[...]. J Thorac Oncol 2016
109
15

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, Adam Langenbucher, Jessica J Lin, Marguerite M Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A Adams, Beow Y Yeap,[...]. Clin Cancer Res 2020
79
15

Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Monica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, Wenjing Zhu, Kaumudi Bhawe, Nerissa Mendoza, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Ling Fu,[...]. Cancer Res 2006
353
15

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu,[...]. Lancet 2017
671
15

Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.
Paolo M Comoglio, Livio Trusolino, Carla Boccaccio. Nat Rev Cancer 2018
178
15

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
D Moro-Sibilot, N Cozic, M Pérol, J Mazières, J Otto, P J Souquet, R Bahleda, M Wislez, G Zalcman, S D Guibert,[...]. Ann Oncol 2019
77
15

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.
Alexis B Cortot, Zoulika Kherrouche, Clotilde Descarpentries, Marie Wislez, Simon Baldacci, Alessandro Furlan, David Tulasne. J Natl Cancer Inst 2017
55
15

Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Thibault Vieira, Nicolas Girard, Mony Ung, Isabelle Monnet, Aurélie Cazes, Pierre Bonnette, Michael Duruisseaux, Julien Mazieres, Martine Antoine, Jacques Cadranel,[...]. J Thorac Oncol 2013
124
15

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Xiuning Le, Hiroshi Sakai, Enriqueta Felip, Remi Veillon, Marina Chiara Garassino, Jo Raskin, Alexis B Cortot, Santiago Viteri, Julien Mazieres, Egbert F Smit,[...]. Clin Cancer Res 2022
14
50

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, Jian-Hua Chang, Gong-Yan Chen, Jian Xing He, Wei Li, Xiao-Qing Liu, Nong Yang, Caicun Zhou,[...]. Invest New Drugs 2021
18
38

Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Eun Kyung Kim, Kyung A Kim, Chang Young Lee, Sangwoo Kim, Sunhee Chang, Byoung Chul Cho, Hyo Sup Shim. Clin Lung Cancer 2019
45
13

Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
Marie Mayenga, Jean-Baptiste Assié, Isabelle Monnet, Marie-Ange Massiani, Laure Tabeze, Sylvie Friard, Séverine Fraboulet, Anne-Cécile Métivier, Christos Chouaïd, Leïla Zemoura,[...]. Lung Cancer 2020
25
24


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.